PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit, your source for clinical literature updates. Today, we’re discussing Phase III data on patient-reported outcomes in rheumatoid arthritis, psoriasis, and psoriatic arthritis treated with GP2015, an etanercept biosimilar. Seth, great to have you here.
Seth: Thanks, Britany. Biosimilars like GP2015 are important for improving access by reducing costs. Clinicians want to ensure switching doesn’t compromise patient-reported outcomes, or PROs.
Britany: Right. Rheumatoid arthritis, psoriasis, and psoriatic arthritis are chronic inflammatory diseases that impair quality of life. Biologics targeting TNF-alpha, like etanercept, have improved clinical and patient-centered outcomes.
Seth: Despite regulatory approvals based on clinical equivalence, there’s hesitation about interchangeability and PRO impact when switching from reference biologics to biosimilars. The Phase III EGALITY and EQUIRA studies provide robust PRO data comparing GP2015 to reference etanercept.
Britany: EGALITY enrolled 531 patients with moderate-to-severe plaque psoriasis, some with psoriatic arthritis. EQUIRA included 376 patients with active rheumatoid arthritis despite methotrexate. Both were double-blind, randomized controlled trials assessing efficacy and PROs over nearly a year.
Seth: EGALITY involved multiple switches between GP2015 and reference etanercept at weeks 12, 24, and 36, reflecting real-world scenarios like formulary changes. EQUIRA maintained continuous treatment for 48 weeks, allowing clean comparison of sustained outcomes.
Britany: Inclusion criteria were clear. EGALITY required moderate-to-severe plaque psoriasis with PASI ≥10, body surface area ≥10%, and DLQI >10; some had psoriatic arthritis. EQUIRA enrolled adults with active rheumatoid arthritis per ACR/EULAR criteria despite methotrexate.
Seth: Patients with prior biologic failure, etanercept hypersensitivity, or significant comorbidities were excluded to ensure appropriate evaluation of the biosimilar’s effects.
Britany: Both studies compared GP2015 to reference etanercept. EGALITY included multiple switches through week 52; EQUIRA had continuous treatment for 48 weeks.
Seth: The primary focus was on PROs: DLQI in EGALITY; and in both studies, EQ-5D-5L for quality of life, FACIT-Fatigue, and HAQ-DI for functional status.
Britany: Results were encouraging. In EGALITY, both groups showed significant, comparable DLQI improvements by week 12, sustained through week 52 despite multiple switches, indicating no negative impact on perceived quality of life.
Seth: EQ-5D-5L scores improved consistently across mobility, self-care, usual activities, pain/discomfort, and anxiety/depression over 52 weeks with no differences between groups, supporting biosimilar equivalence in functional outcomes.
Britany: HAQ-DI scores decreased similarly in patients with psoriatic arthritis and rheumatoid arthritis. Comparable proportions achieved normal range scores (HAQ-DI ≤0.5) up to week 48 in EQUIRA and week 52 in EGALITY.
Seth: Fatigue improved from baseline in EQUIRA and was sustained through week 48 regardless of switching. This is important since fatigue often poorly correlates with clinical measures but greatly affects quality of life.
Britany: No negative impact on PROs or quality of life was observed after biosimilar switching, supporting interchangeability critical for clinicians and pharmacists.
Seth: These findings align with prior research: Genovese et al. (2019) confirmed comparable efficacy and safety of etanercept biosimilars in rheumatoid arthritis; Richter et al. showed patient-reported disease control in psoriasis; Burmester et al. demonstrated unaffected immunogenicity and efficacy after switching.
Britany: Including multiple PRO measures is a strength, providing a multidimensional view of patient well-being beyond clinical endpoints.
Seth: Limitations include follow-up of 48 to 52 weeks, which is robust but relatively short for chronic diseases. Long-term PRO data after biosimilar switching remain limited.
Britany: Also, EGALITY’s switching was at predefined timepoints; real-world switching may be more variable due to insurance, patient preference, or adverse events. Ongoing clinical monitoring is essential.
Seth: Clinically, pharmacists and clinicians can be confident GP2015 offers equivalent patient-reported quality-of-life benefits compared to reference etanercept across RA, PsA, and PsO. Multiple switches do not negatively impact patient perceptions or fatigue.
Britany: This reassures patient counseling, as concerns about switching can affect adherence. Evidence that switching doesn’t compromise quality of life supports shared decision-making.
Seth: Ongoing patient communication and PRO monitoring remain important, as individual experiences vary and fatigue or functional impairment may persist despite clinical improvements.
Britany: Also, consider potential drug interactions. Etanercept and biosimilars can interact with immunosuppressants or live vaccines, so medication reconciliation and patient education are essential.
Seth: Special populations like elderly or those with comorbidities were generally excluded, so clinicians should be cautious applying findings to complex patients.
Britany: To sum up, EGALITY and EQUIRA provide robust evidence that GP2015 delivers sustained PRO improvements comparable to reference etanercept in rheumatoid arthritis, psoriasis, and psoriatic arthritis. Multiple switches did not adversely affect quality of life or fatigue.
Seth: This supports confident biosimilar substitution in practice, aligning with American College of Rheumatology and EULAR guidelines endorsing biosimilars as effective and safe alternatives.
Britany: Thanks for the discussion, Seth. Listeners, we encourage reviewing Thaçi et al. in Drugs R&D, 2025, for more detail. Keep patient-centered outcomes central in your clinical decisions.
Seth: Thanks, Britany. Staying informed on biosimilar data helps optimize therapy and improve access without compromising care quality.
Britany: That’s today’s PACULit update. Stay tuned for more evidence-based insights to support your practice. Until next time!
Seth: Before we wrap up, Britany, I think it’s worth highlighting how these studies also contribute to the broader conversation about healthcare sustainability. Biosimilars like GP2015 not only maintain clinical and patient-reported outcomes but also have the potential to reduce overall treatment costs significantly.
Britany: Absolutely, Seth. Cost savings from biosimilars can improve healthcare system efficiency, allowing more patients to access biologic therapies earlier in their disease course, which may prevent long-term disability.
Seth: And from a patient perspective, improved access means fewer barriers to starting or continuing effective treatment, which can translate into better disease control and quality of life over time.
Britany: That’s a great point. Also, the psychological impact of switching shouldn’t be underestimated. Some patients worry about changing medications, fearing loss of efficacy or new side effects. The robust PRO data from EGALITY and EQUIRA help clinicians reassure patients that switching is safe and effective.
Seth: Right, and incorporating patient education about biosimilars into clinical practice can enhance adherence and trust. When patients understand that biosimilars undergo rigorous evaluation and demonstrate comparable outcomes, they’re more likely to accept treatment changes.
Britany: Looking ahead, it will be interesting to see real-world evidence accumulate, especially regarding multiple switches beyond those studied in clinical trials, and in more diverse patient populations.
Seth: Yes, and ongoing pharmacovigilance will be key to monitoring long-term safety and immunogenicity, ensuring that biosimilar use continues to meet high standards.
Britany: For now, the data support integrating GP2015 confidently into treatment algorithms for RA, PsA, and psoriasis, with attention to patient-reported outcomes as a vital component of comprehensive care.
Seth: Well said. Thanks again for the insightful discussion, Britany.
Britany: Thank you, Seth. And thanks to our listeners for joining us on PACULit. Stay engaged with the latest research to provide the best care possible. See you next time!